INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 133 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2015. The put-call ratio across all filers is 2.26 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $5,871,000 | +50.8% | 228,700 | -23.8% | 0.55% | +3.6% |
| Q2 2019 | $3,894,000 | +6.6% | 300,000 | 0.0% | 0.53% | +59.6% |
| Q1 2019 | $3,654,000 | +40.4% | 300,000 | +519.8% | 0.33% | -12.3% |
| Q4 2015 | $2,603,000 | -38.3% | 48,400 | -54.1% | 0.38% | -29.2% |
| Q3 2015 | $4,220,000 | +3.2% | 105,400 | -17.7% | 0.54% | +34.2% |
| Q2 2015 | $4,090,000 | +14.2% | 128,000 | -14.7% | 0.40% | +7.5% |
| Q1 2015 | $3,582,000 | +125.3% | 150,000 | +59.1% | 0.37% | -4.8% |
| Q2 2014 | $1,590,000 | -12.5% | 94,300 | -5.7% | 0.39% | -5.5% |
| Q1 2014 | $1,818,000 | – | 100,000 | – | 0.42% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |